AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ZTS

Zoetis: Q3 Earnings Snapshot

Zoetis Inc. (ZTS) reported Q3 profit of $591M, or $1.44 per share, exceeding expectations. Revenue was $2.39B, also topping forecasts. The company raised full-year earnings guidance to $6.25-$6.35 per share and revenue to $9.22B-$9.32B.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Zoetis: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ZTSBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to trigger short-covering and new buying, supporting a price uptick.

02

Market read

First-report earnings with material beat and guidance raise for a large-cap health company.

03

What to watch

Potential headwinds from regulatory scrutiny or foreign exchange impacts on overseas sales.

Relevance 9/10Novelty 9/10Timing: post-market today

Background

Zoetis is the leading animal health company, listed on NYSE under ZTS.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis reported Q3 profit of $591M and revenue of $2.39B, both beating Zacks estimates, and raised full-year guidance.

Expected impact

upward pressure as the market prices in the earnings beat and higher guidance

Evidence & confidence

The company exceeded consensus on earnings and revenue and provided a higher-than-expected full-year outlook, which typically drives buying interest.

Market effects

Sector

Animal health sector may see broader rally on strong earnings from its largest player.

Regional

U.S. biotech and pharma investors could see increased risk appetite.

Global

Limited to investors tracking global healthcare equities.

Counterpoint

What could challenge this read

If the market had already priced in a strong quarter, the beat may be muted.

Key entities

  • company
    Zoetis Inc.

    Animal health pharmaceutical company.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

6 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com